报 告 题 目：VEGF-C and its activation in lymphangiogenesis
报 告 人：Michael Jeltsch, PhD, Associate professor, University of Helsinki
主 持 人：何玉龙 教授
报告时间：2021年1月21日（星期四），下午16:00-17:00
报告地址：（1）独墅湖校区703楼唐仲英医学研究院 血液学研究中心703号
（2）线上会议软件参会（Zoom 会议号：845 0445 2229，密码：1f5kYK）
报告人简介
Michael Jeltsch, PhD, Associate professor, University of Helsinki.
Dr. Jeltsch was the first to show that VEGF-C and VEGF-D are growth factors for the lymphatic vasculature. His research focuses on lymphangiogenesis and protein technologies, with 75 publications (H-index 36, 10628 citations from web of science) in famous journals such as Science, Blood and Circulation. He developed a synthetic super-VEGF, using a novel, non-random DNA shuffling method and is developing a Crispr/Cas technology to do antibody affinity maturation within a few days in vitro. Three of his biologics are in human clinical trials (VGX-100, OPT-302/VGX-300, Lymfactin).
